PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-23.20%
Negative net income growth while TRVN stands at 11.17%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.49%
Some D&A expansion while TRVN is negative at -2.29%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-100.00%
Negative yoy deferred tax while TRVN stands at 90.32%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
19.58%
SBC growth while TRVN is negative at -2.84%. John Neff would see competitor possibly controlling share issuance more tightly.
19.36%
Well above TRVN's 7.19% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.56%
A yoy AP increase while TRVN is negative at -17.25%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-124.52%
Negative yoy usage while TRVN is 73.18%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
56.31%
Some yoy increase while TRVN is negative at -73.78%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-16.84%
Negative yoy CFO while TRVN is 8.63%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth of 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have mild expansions while TRVN is negative at -70.83%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-594.74%
Both yoy lines negative, with TRVN at -59.26%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.